Park Young Shil, Shin Won-Ju, Kim Kang-Il
Department of Pediatrics, Kyung Hee University Hospital at Gangdong, School of Medicine, Kyung Hee University, 892, Dongnam-ro, Gangdong-Gu, Seoul, 05278, Korea.
Department of Orthopedic Surgery, Kyung Hee University Medical Center, 23, Kyungheedae-ro, Dongdaemun-gu, Seoul, 0244, Korea.
BMC Musculoskelet Disord. 2017 Aug 22;18(1):356. doi: 10.1186/s12891-017-1720-0.
Total knee arthroplasty (TKA) has become the treatment of choice for end-stage hemophilic arthropathy of the knee. Theoretically in hemophilia A, perioperative continuous infusion (CI) of factor VIII (FVIII) would provide a more consistent FVIII level than general bolus injections (BI) in TKA. Current study was designed to evaluate the effectiveness of CI of coagulation factor concentrates during the perioperative period compared to BI.
A total of 42 TKAs were performed in 31 patients with severe hemophilia A. Under the supervision of a multidisciplinary hemophilia team, CI and BI were monitored during application of a standardized regimen. Perioperative clinical parameters including postoperative hemoglobin drop, drained blood volume, transfusion rate, total consumption of FVIII, and perioperative complications were assessed.
The difference in the postoperative hemoglobin drop was significant between two groups with a lower decrease in the CI group (p = 0.002). The drained blood volume for postoperative 24 h was significantly lower in the CI than the BI groups (p = 0.037). Total consumption of factor concentrates for postoperative 5 days was greater in the CI group than in the BI group (p = 0.000). One postoperative hematoma and wound dehiscence occurred in BI group and no other complication developed.
Although good control of hemostasis could be achieved using either method during the perioperative period of TKA, CI seems more tolerable and effective than BI to provide perioperative blood management undergoing TKA in patients with hemophilia.
The study was retrospectively registered in WHO ICTRP under identifier KCT0002404 (date of registration: August 04, 2017).
全膝关节置换术(TKA)已成为晚期膝关节血友病性关节病的首选治疗方法。理论上,在甲型血友病患者的全膝关节置换术中,围手术期持续输注(CI)凝血因子VIII(FVIII)比一次性大剂量注射(BI)能提供更稳定的FVIII水平。本研究旨在评估与一次性大剂量注射相比,围手术期凝血因子浓缩物持续输注的有效性。
对31例重度甲型血友病患者进行了42次全膝关节置换术。在多学科血友病治疗团队的监督下,在应用标准化方案期间监测持续输注和一次性大剂量注射情况。评估围手术期临床参数,包括术后血红蛋白下降、引流血量、输血率、FVIII总消耗量和围手术期并发症。
两组术后血红蛋白下降差异有统计学意义,持续输注组下降幅度较小(p = 0.002)。持续输注组术后24小时引流血量明显低于一次性大剂量注射组(p = 0.037)。持续输注组术后5天凝血因子浓缩物总消耗量高于一次性大剂量注射组(p = 0.000)。一次性大剂量注射组发生1例术后血肿和伤口裂开,未出现其他并发症。
虽然在全膝关节置换术围手术期使用这两种方法均可实现良好的止血控制,但对于血友病患者接受全膝关节置换术的围手术期血液管理,持续输注似乎比一次性大剂量注射更耐受且有效。
该研究已在世界卫生组织国际临床试验注册平台(WHO ICTRP)进行回顾性注册,标识符为KCT0002404(注册日期:2017年8月4日)。